Author:
Geynisman Daniel M.,Stadler Walter M.
Publisher
Springer International Publishing
Reference130 articles.
1. Albiges L, Guegan J, Le Formal A, Verkarre V, Rioux-Leclercq N, Sibony M, Bernhard JC, Camparo P, Merabet Z, Molinie V, Allory Y, Orear C, Couve S, Gad S, Patard JJ, Escudier B (2014) MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res 20(13):3411–3421
2. Allory Y, Ouazana D, Boucher E, Thiounn N, Vieillefond A (2003) Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases. Virchows Arch 442(4):336–342
3. Amato RJ, Khan M (2008) A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. Cancer Chemother Pharmacol 61(6):1069–1073
4. Amin MB, Paner GP, Alvarado-Cabrero I, Young AN, Stricker HJ, Lyles RH, Moch H (2008) Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol 32(12):1822–1834
5. Ansari J, Fatima A, Chaudhri S, Bhatt RI, Wallace M, James ND (2009) Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie 32(1–2):44–46